Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer

A Phase I trial of recombinant vaccinia prostate specific antigen (rV‐PSA) in patients with advanced metastatic prostate cancer was conducted. This report describes 42 patients who were treated with up to three monthly vaccinations.

[1]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[2]  J. Schlom,et al.  Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. , 2001, Cancer research.

[3]  J. Schlom,et al.  Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. , 2001, Cancer research.

[4]  E. Gehan,et al.  Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Steinberg,et al.  The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines , 2000, Cancer Immunology, Immunotherapy.

[6]  G. Weiner,et al.  Uses of granulocyte-macrophage colony-stimulating factor in vaccine development , 2000, Current opinion in hematology.

[7]  P. Kantoff,et al.  A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  J. Schlom,et al.  A triad of costimulatory molecules synergize to amplify T-cell activation. , 1999, Cancer research.

[9]  J. Schlom,et al.  The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. , 1999, Vaccine.

[10]  K. Pienta,et al.  Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. , 1999, Urology.

[11]  J. Schlom,et al.  Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. , 1998, Journal of immunology.

[12]  S. Rosenberg,et al.  Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. , 1997, Journal of the National Cancer Institute.

[13]  J. Schlom,et al.  Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. , 1997, Vaccine.

[14]  J. Schlom,et al.  In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. , 1997, Journal of the National Cancer Institute.

[15]  H. Rammensee,et al.  A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  A. García-Sastre,et al.  Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. , 1996, Cellular immunology.

[17]  R. Barth,et al.  Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes , 1996, Cancer Immunology, Immunotherapy.

[18]  J. Schlom,et al.  Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. , 1996, Cancer research.

[19]  J. Schlom,et al.  A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate , 1995, International journal of cancer.

[20]  J. Schlom,et al.  Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. , 1995, Journal of the National Cancer Institute.